Rossari Targets 12–13% EBITDA Margin Despite Raw-Material Pressure

Rossari Biotech Limited — Q4 & FY26 Earnings Call (held Apr 28, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “very strong note” and “highest-ever quarterly revenue and EBITDA performance.”
• They express confidence in growth acceleration: “well placed to drive the next phase of growth” and “accelerate growth over the next 2 to 3 years.”
• However, they repeatedly acknowledge external uncertainty (Middle East conflict, raw material volatility) and keep some guidance conservative (EBITDA margin “between 12% to 13%”).

2. Key Themes from Management Commentary

• Growth delivery + volume-led performance: FY26 revenue growth of 15%, “primarily volume driven,” with “healthy traction across businesses.”
• R&D pivot to platform technologies: moving “from a formulation-led approach towards… broader platform technologies,” with biosurfactants (“sustainable chemistries, including biosurfactants gaining traction”).
• Capacity expansion to improve supply reliability and utilization:
• Unitop ethoxylation capacity commissioned/expanded to 66,000 MTPA (Dahej).
• Thailand blending unit commissioned (later ramp from Q2 FY27).
• Premix facility commissioned (revenues starting “this quarter”).
• International momentum + strategic KSA expansion:
• Exports grew 11% YoY in FY26; expansion into Latin America, Europe, Southeast Asia, Africa.
• Saudi Arabia initiative framed as long-term manufacturing footprint strengthening; management remains “confident” despite geopolitics.
• Margin pressure acknowledged; operating leverage expected later:
• EBITDA margin down vs FY25 (11.9% vs 12.7%) due to raw material price increases (25–30%), mix, and cost environment.
• Expectation: operating leverage as investments scale and utilization improves.
• Portfolio rationalization + cost optimization (especially consumer/institutional):
• Domestic institutional/B2C described as “subdued” with “calibrated steps to optimize costs and improve operational efficiencies.”
• Plan to sell “non-core assets” (office space already sold; more planned).

3. Q&A Analysis

Theme A: FY27 outlook—growth and EBITDA margin

• Core questions:
• What should shareholders expect for FY27 top-line growth and consolidated operating margins/EBITDA margins, given Iran war/raw material increases?
• Management response:
• Growth: “minimum similar kind of growth” as FY26; “hopefully… much better” if conditions improve.
• EBITDA margin: “remain at these current levels between 12% to 13%.”
• Margin improvement levers: better-margin segments (pharma “by second half”).
• Notable/partial or evasive elements:
• No explicit numeric revenue guidance; relies on “minimum similar” language.
• Margin guidance is firm (12–13%) but improvement path is qualitative.

Theme B: Segment economics / margin structure

• Core questions:
• Segment-wise EBITDA/gross margin profiles for HPPC, textiles, AHN; which segment is highest/lowest margin.
• Management response:
• They refused segment EBITDA margin disclosure: “This data we do not put forth.”
• Qualitative: AHN highest gross margin; within HPPC agro/oil & gas better; pharma expected to become highest gross margin “once… reasonable size.”
• Evasive/partial:
• Multiple questions on segment margins were deflected; only broad qualitative statements provided.

Theme C: Raw material sourcing, pass-through, and EO availability

• Core questions:
• Crude-linked RM exposure; EO supply stability; ability to pass through price increases; any demand-side challenge.
• Management response:
• RM supply “stable,” “no stock shortages.”
• EO supply “very stable”; they claim no Middle East buying: “we are not buying anything from the Middle East now.”
• Pass-through: “no challenge… pass-through is easy”; some resistance in textile but they control supply and pricing.
• Demand: “There is no demand side challenge, orders remain robust.”
• Strong/credible signals:
• Utilization claim for ethoxylation: “practically 90% to 100%” and “no… downtime” (except expansion).

Theme D: CAPEX rephasing—why delayed and how much in FY27; debt reduction

• Core questions:
• Why CAPEX postponement; FY27 CAPEX number; debt trajectory and whether they’ll become debt-free.
• Management response:
• Delay explanation: Reliance capacity expansion revisions → Rossari moderated capex; also earlier capex delays; rephased spend for cash flow/ROCE.
• FY27 CAPEX: “anything between Rs. 50 crore to Rs. 75 crore… not… more than… Rs. 70–75 crore.”
• Debt: long-term debt “~Rs. 200-odd crore”; plan to reduce debt significantly; “target is to actually get debt free in the next 18 months” (with caveat “time will tell”).
• Non-core asset sales: office space already sold; “more of these we plan to do.”
• Notable evasiveness:
• Divestment timeline/value: refused to “hazard any number” and gave broad “2027… could take… 1–2 years.”

Theme E: Utilization ramp-up and commissioning timelines

• Core questions:
• Current utilization of ethoxylation after expansion; utilization of Unitop capacity; whether premix plant delayed.
• Management response:
• Ethoxylation utilization: “90% to 100%.”
• Unitop utilization: “ramping up… better than Q3” but no exact figure.
• Premix plant: “already been commissioned” and revenues starting “this quarter.”
• Partial answers:
• Utilization asked numerically; they often respond qualitatively (“ramping up”) without exact Q4 utilization.

Theme F: Institutional/B2C losses—breakeven timing

• Core questions:
• When will institutional business breakeven (FY27 vs FY28)?
• Management response:
• “In FY27, we should look at breakeven or even profitability… along with divestment of some lower-margin businesses.”
• Credibility note:
• Breakeven is stated as expectation, but tied to divestments and margin actions—no hard metrics.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 EBITDA margin (consolidated): “between 12% to 13%.”
• FY27 top-line growth: no numeric figure; “minimum similar kind of growth” as FY26 (FY26 was 15%).
• FY27 CAPEX: “Rs. 50 crore to Rs. 75 crore” (upper bound “Rs. 70–75 crore”).
• Ethoxylation utilization: “practically 90% to 100%.”
• Thailand facility revenue potential: “Rs. 50 crore to Rs. 75 crore at peak” (but “will not reach Rs. 50 crore in this year itself”).
• Debt reduction target: “debt free in the next 18 months” (softened by “time will tell”).

Implicit signals (qualitative)

• Margin improvement path: shift to “better margin segments like pharma” (second half), and “sell some assets and businesses that are not core.”
• Demand outlook: “no fall in demand,” “orders remain robust,” and “global situation… do not see any fall in demand.”
• Operating leverage timing: margin improvement expected as utilization improves and investments scale up (“over the coming years”).
• Institutional/B2C: losses expected to moderate; breakeven in FY27 “along with divestment.”

5. Standout Statements (direct quotes where useful)

• Performance peak: “Q4 marking our highest-ever quarterly revenue and EBITDA performance.”
• Margin floor guidance: “EBITDA margins will remain… between 12% to 13%.”
• Growth stance: “minimum similar kind of growth that we have done in this year.”
• Raw material confidence: “We do not have stock shortages for any raw materials.”
• EO supply + operations: “Ethylene Oxide supply also is very stable” and ethoxylation utilization “practically 90% to 100%.”
• CAPEX rephasing rationale: “rephase… in light of evolving business requirements and the market conditions” and Reliance plan changes.
• Debt ambition: “target is to actually get debt free in the next 18 months.”
• Institutional breakeven: “In FY27, we should look at breakeven or even profitability…”
• Non-core divestment refusal to quantify: “No… we would not like to hazard any number.”

6. Red Flags / Positive Signals

Positive signals
– Strong operational execution: highest-ever Q4 revenue/EBITDA.
– Clear margin “floor” (12–13%) plus stated levers (pharma mix, asset sales, value-added products).
– EO utilization and supply confidence are specific (90–100%, “no downtime”).
– CAPEX discipline: FY27 capex capped at 50–75 cr.

Red flags
– Segment margin opacity: repeated refusal to share segment-wise EBITDA margins.
– Guidance is conservative and conditional: growth “minimum similar” without numeric revenue; margin improvement depends on mix and divestments.
– Divestment uncertainty: no timeline/value; “could take more than a year, 2 years.”
– Utilization precision gaps: asked for exact utilization; management often gives ranges/qualitative ramp-up.
– Geopolitical risk acknowledged but not quantified: Middle East conflict “may have an impact over the coming quarters.”

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current call (Apr 2026): more optimistic—“very strong note,” “highest-ever” Q4, confidence in FY27 growth “minimum similar.”
• Prior calls:
• Q3 FY26 (Jan 2026): optimistic but more cautious on EO constraint (“Availability of EO continues to be a near-term constraint”).
• Q2 FY26 (Oct 2025): optimistic on growth momentum; still highlighted EO availability as a constraint but expected easing.
• Q4 FY25 (Apr 2025): optimistic on platform (Renewa) and capacity commissioning; less explicit geopolitical risk framing.
• Shift classification: More Optimistic than Q3 FY26, mainly because EO/operations are now described as stable and Q4 performance is peak.

b. Tracking Past Commitments vs Outcomes

1. Operating leverage timing to reach 13% EBITDA (from Q3 FY26 call)
2. Past statement (Q3 FY26, Jan 2026): operating leverage “around 2027” to reach optimal utilization and margin upside.
3. What happened / current call: FY26 EBITDA margin ended at 11.9% (below 12.7% FY25). FY27 guidance is still 12–13%, not a clear move to 13%+.

4. Flag: ⏳ Delayed / Not yet delivered (margin uplift not yet realized; still guiding 12–13%).

5. EO availability easing

6. Past (Q3 FY26): EO constraint expected to ease during calendar year; ramp-up plan.
7. Current (Q4 FY26): EO supply described as “very stable,” ethoxylation utilization “90% to 100%.”

8. Flag: ✅ Improved / Delivered (at least operationally in FY26 end).

9. CAPEX commissioning cadence

10. Past (Q4 FY25): expansions expected commissioning by Q2 FY26; later capex phased by Q4 FY26.
11. Current: management now states rephasing and “re-evaluation” of broader investment plans; FY27 capex reduced to 50–75 cr.

12. Flag: ⏳ Rephased / Partially delayed (not necessarily failed, but commitment to spend/commission appears less linear).

13. Consumer/institutional breakeven

14. Past (Q4 FY25): consumer/institutional scaling expected; margin improvement as scale/operational maturity builds.
15. Current: institutional breakeven targeted FY27 but explicitly tied to divestments and margin actions.
16. Flag: ⏳ Not yet proven; conditional.

c. Narrative Shifts

• From “invest for future margin expansion” → “sell non-core to improve margins.”
• Earlier calls emphasized scaling emerging verticals and operating leverage.
• Now, management explicitly says margins should improve “automatically” once consumer/institutional businesses are sold.
• Saudi/KSA story persists but becomes more operationally grounded
• Q3 FY26: KSA was “in-principle approval” and evaluation.
• Q4 FY26: still long-term, but now framed as confidence despite geopolitics and linked to supply competitiveness.
• More emphasis on cash/debt and asset liquidation
• Office space sale already monetized; more non-core asset sales planned; debt reduction target stated.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: operational claims (EO stability, utilization range) are specific.
• Weakness: repeated deferrals/softening on divestment timelines and segment margin transparency.
• Margin trajectory has not yet matched earlier “operating leverage” expectations (still guiding 12–13% for FY27).

e. Evolution of Key Themes

• Demand: from “muted/soft domestic” (Q2/Q3 FY26) to “no demand fall” (Q4 FY26), though still “soft during certain periods.”
• Margins: persistent pressure; FY25→FY26 margin decline; FY27 guidance keeps a floor rather than promising expansion.
• International: exports remain a growth engine (Q2/Q3 showed stronger export growth; FY26 still positive but at 11% YoY—slower than earlier quarters’ momentum).
• R&D/biosurfactants: consistently highlighted; now includes traction and approvals (“best personal care company… approved our bio-surfactants”).
• Capital allocation: shift toward rephasing CAPEX and asset monetization.

f. Additional Insights (cross-period intelligence)

• Margin improvement is increasingly dependent on structural actions (divestments) rather than purely operational leverage.
• This is a subtle but important shift: earlier narrative leaned on scale/utilization; now it leans on “sell non-core” to lift consolidated margins.
• Conservative FY27 EBITDA guidance despite “new capacities on stream”
• Suggests either (i) mix headwinds persist, (ii) consumer/institutional drag continues, or (iii) raw material/cost volatility remains unresolved.